Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:
“Pleased to share the publication of the design of the phase III PRODIGE 98 – AMPIRINOX trial in resected ampullary adenocarcinoma, a rare epithelial digestive cancer where the optimal adjuvant strategy remains debated.
Beyond clinical outcomes, this study integrates an extensive translational program combining pathology, genomics and transcriptomics to better understand tumor subtypes and treatment response.
Our contribution is articulated through OncoSignView, a cross-tumor transcriptomic framework dedicated to transferring and refining chemotherapy-response signatures across epithelial cancers.
Starting from PancreasView, originally developed for PDAC treatment-response prediction, we aim to evaluate how predictive transcriptomic patterns can be extended beyond pancreatic cancer to other epithelial gastrointestinal tumors treated with FOLFIRINOX or gemcitabine-based regimens, while explicitly accounting for both epithelial and stromal composition.
This is not a fixed model but an ongoing scientific exploration, moving predictive signatures from one tumor context to another to approach a more organ-agnostic precision oncology grounded in biology and data.
A truly collective effort bridging clinical oncology, molecular pathology and machine-learning-driven translational research.”
Title: Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma
Authors: GaelS. Roth a, Jérôme Cros, Cindy Neuzillet, Emilie Barbier, Meriem Guarssifi, Amel Bennacer, Michel Ducreux, Marie Muller, Julien Edeline, Sylvain Manfredi, Nicolas Williet, Nelson Dusetti, Pierre Laurent-Puig, Victoire Ruffino, Brice Chanez, Rémy Nicolle, Julien Taieb, David Malka
Read the full article.
More posts featuring Nelson Dusetti on OncoDaily.